Single-nucleus sequencing unveils heterogeneity in renal cell carcinomas microenvironment: insights into pathogenic origins and treatment-responsive cellular subgroups

Cancer Letters, Journal Year: 2024, Volume and Issue: 604, P. 217259 - 217259

Published: Sept. 13, 2024

Language: Английский

---

Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Cancer patients treated with current chemotherapeutic and targeted therapies frequently achieve partial remission, which ultimately relapse more aggressive, drug-resistant tumor phenotypes. To a certain extent, drug-tolerant persister (DTP) cells are responsible for residual tumors after systemic anticancer therapy the onset of acquired drug resistance. Therefore, novel targeting DTP to prevent resistance recurrence urgently needed. We aimed investigate traits key vulnerabilities ovarian cancer seek out potential therapeutic strategies. constructed paclitaxel-tolerant by exposing parental lethal dose paclitaxel. Proteomics analysis, in vitro vivo assays were performed identify biological processes that could serve as cells. Paclitaxel-tolerant found undergo metabolic reprogramming through upregulation fatty acid oxidation (FAO). Treatment FAO inhibitor ST1326 suppressed increased sensitivity paclitaxel Moreover, combination prevented satisfactory biosafety mouse model relapse, indicating disruption can improve efficacy paclitaxel-based cancer. Mechanistically, we treatment upregulated CEBPB, transcription factor induced expression FAO-related enzyme HADHA contributed elevation This study revealed an provided prospective paclitaxel-ST1326 may development superior long-term control future. Our research established conceptual framework advancing personalized approaches enhancing patient outcomes therapy.

Language: Английский

---

Deformable Dual Graph Aggregation Transformer Convolutional Networks with Spider Wasp Optimizer for Ovarian Tumor Classification Using Magnetic Resonance Imaging

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Language: Английский

---

Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches

The EPMA Journal, Journal Year: 2024, Volume and Issue: 15(4), P. 711 - 737

Published: Nov. 25, 2024

Language: Английский

---

A Paradigm Shift on Emergence of Pharmacogenomics in the Era of Personalized Medicine

Advances in medical technologies and clinical practice book series, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 34

Published: Dec. 13, 2024

Pharmacogenomics is the study of genetic modifications in patients that influence their potential to metabolize medications, encouraging tolerability and desired effect. Genetic (like genome-wide association & candidate gene) methods may help choosing most suitable drug dosage, by impeding adverse reactions (ADRs). are usually documented as key steps personalized medicine. The significance medicine healthcare developing due its defined molecular basis. Personalized anticipates beneficial or serious side effects a medication using specific individual's profile. In recent year's pharmacogenomics approaches being widely used personalizing therapies for diseases like Cancer, Rheumatoid arthritis, Asthma, Type-1 diabetes many psychiatric disorders (depression, psychosis, schizophrenia etc.).This chapter provides an overview present importance identifies challenges need be conquered effective

Language: Английский

---

Design of a Smart Physiological Monitoring System for the Elderly to Enable Predictive, Preventive, and Personalized Medicine

Published: Dec. 27, 2024

Language: Английский

---